N/A N=33 Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination
HIV · Rabies
Primary: Rabies Neutralizing Antibody Titers — 8.48 IU/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=43 Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Immunosuppression
Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants
N/A N=241 Zoster Vaccine Response in the Frail Elderly
Immune System Diseases
Primary: Change From Baseline in T-cell Response to the VZV Vaccine in the Frail Elderly — 50.17; 78.17; 83.22; 120.56 Spot Forming Units per 10^6 PBMC
Phase 4 N=20 The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
Influenza
Primary: Change in Geometric Mean Serum Hemagglutination Inhibition (HAI) Antibody Titer — 23; 56.5; 188; 108 HAI antibody Titers
N/A N=28 The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus
RSV Infection
Primary: Number of Participants With Challenge-related Adverse Events — 0; 3 Participants
N/A N=174 Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)
Vaccine Response Impaired
Primary: Antibody Titer Responses to Hepatitis B Virus Surface Antigen (HBV sAg) Vaccine, Measured and Predicted Based on Pre-vaccination Biomarkers in Healthy, Elderly…
Phase 4 N=136 Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)
Influenza
Primary: Number of Participants Who Received the Influenza Vaccine — 59; 37; 40 Participants
Phase 4 N=10 Senescent Immunity in Elders and Vaccine Responses (SILVER)
Flu Vaccine
Primary: Hemagglutinin Antigen Inhibition Assay Titers at Baseline — 20; 160; 25; 40 antibody titers
Phase 4 N=15 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
Inflammatory Bowel Disease · Uterine Cervical Dysplasia
Primary: Twelve Month Antibody Response to the Human Papillomavirus (HPV) Vaccine (Geometric Mean Titers [GMT]) — 120.5; 175.0; 861.0; 68.9 mMU/mL
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Phase 2 N=34 Effects of Age on Response to the 2009 H1N1 Virus Vaccine
2009 H1N1 Influenza Virus
Primary: Number of Participants Who Shed Virus — 0 participants
N/A N=88 Systems Biology of PNEUMOVAX®23 and PREVNAR 13®
Pneumococcal Infection
Primary: Number of Participants With Innate Immunity Signatures That Correlate With the Quality of Antibodies After PNEUMOVAX and PREVNAR - Monocyte Module M4.15 — 1; 2; 0; 2…
Phase 2 N=71 Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Relapsing Forms of Multiple Sclerosis
Primary: Percentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level — 73; 68 percentage of participants — p=0.692
N/A N=105 Cell Mediated Immunity in Older Adults
Immunity to Influenza Vaccine
Primary: Cellular Immune Response — 0.239; 0.137; 0.243; 0.160 percentage of Stimulated cells
N/A N=201 COVID19 OutcomeS in Myeloma and the Impact of VaCcines
Multiple Myeloma
Primary: Feasibility of Obtaining Baseline Clinical and PRO Data Capture From 200 Consented Patients. — 196 Participants
N/A N=308 COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Immunodeficiencies · Immune Dysregulations
Primary: Change in S and Receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody Titer From Baseline Depending on Vaccine Manufacturer and Platform — 0.447333; 2.10678…
N/A N=50 Effect of Obesity on Immune Response to Pneumovax 23
Obesity
Primary: Anti-pneumococcal Antibodies Between the Groups — 34.1; 19.8 titer
Phase 1 N=86 Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders
Pneumococcal Infections
Primary: Immune Responses — 1.95; 1.69; 1.22; 0.78 ug/mL
Phase 4 N=241 Gene Signatures of Influenza Vaccine Responses in Older Adults
Influenza
Primary: Innate Cell IFNa2a Production — 112.3650; 131.4214; 107.5846; 134.9071 pg/mL
N/A N=66 Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly
Influenza
Primary: Efficacy, Measured by the Number of Subjects With a Change in Innate Immune Signatures — 22; 44 participants
N/A N=52 Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy
Inflammatory Bowel Disease
Primary: Antibody Titer to HPV 6 — 1079.9; 173.4 milli-Merck units/mL
Phase 4 N=91 B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 14; 38; 36 Participants
Phase 4 N=78 The Influence of Chronic CMV Infection on Influenza Vaccine Responses
Cytomegalovirus Infections · Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 33; 37; 8 Participants
Phase 4 N=539 COVID-19 Vaccination of Immunodeficient Persons (COVAXID)
Covid19
Primary: Assessment of Seroconversion, Defined as Development of Immunoglobulin G (IgG) Antibodies Against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) After…
Phase 4 N=54 T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
Herpes Zoster
Primary: Number of Participants Who Received Zostavax Immunization or Had Natural Exposure to VZV — 45; 9 Participants
Phase 4 N=8 B-cell Immunity to Influenza (SLVP017)- Year 5, 2013
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 1; 7 Participants
N/A N=67 Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Percentage of Patients 9-15 Years of Age With CKD Achieving Seropositivity (IgG Assay) at Blood Draw 2 — 100; 100; 100; 100 percentage of participants
N/A N=193 Immune Responses Induced by Different Licensed Influenza Vaccines
Immune Response
Primary: T Cell Responses Following Immunization — 1.5; 1.7; 1.9; 1.6 fold change
Early Phase 1 N=32 Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
Chronic Lymphocytic Leukemia (CLL) · Waldenstrom Macroglobulinemia (WM)
Primary: Number of Participants With Humoral Response to Vaccination 4 Weeks After the Second Vaccine Administration — 24 Participants
Phase 4 N=103 Immune and Hormone Response to Influenza Vaccine
Healthy
Primary: Change in Levels of Progesterone After Influenza Vaccination — 0.62; 0.43; 0.73; 0.59 ng/ml